SeaDragon announced that it has begun a transition to new leadership. The company's chairman Doug Wilson has advised the company to stand down from the board to reduce his workload and focus on his pharmaceutical development interests. The company's board has accepted Wilson's resignation with regret and has started a search for a new chairman.

In the interim, Wilson has indicated he is happy to stay on as chairman until a replacement is found. Meanwhile, the company's chief executive officer Ross Keeley has also advised the board of his intention to step aside to allow him to spend more time on his other business interests, including his dairy farm in Canterbury and other directorships. Mr. Keeley, who has led the company for 11 years, has agreed to remain as chief executive officer until a new chairman is appointed and help the board in the recruitment process for a new CEO.

In the longer term, Mr. Keeley will continue to be engaged by SeaDragon as a consultant to further enhance the supply chain of the Squalene and Omega 3 segments of the business.